Francisella tularensis type B Delta dsbA mutant protects against type A strain and induces strong inflammatory cytokine and Th1-like antibody response in vivo

0506543 - MBÚ 2020 RIV GB eng J - Článek v odborném periodiku
Strašková, Adéla - Špidlová, P. - Mou, S. - Worsham, P. - Putzová, D. - Pavková, I. - Stulík, J.
Francisella tularensis type B Delta dsbA mutant protects against type A strain and induces strong inflammatory cytokine and Th1-like antibody response in vivo.
Pathogens and Disease. Roč. 73, č. 8 (2015), č. článku ftv058. ISSN 2049-632X. E-ISSN 2049-632X
Institucionální podpora: RVO:61388971
Klíčová slova: tularemia * cytokines * antibody response
Obor OECD: Microbiology
Impakt faktor: 2.483, rok: 2015
Způsob publikování: Open access
https://academic.oup.com/femspd/article/73/8/ftv058/2467550

Francisella tularensis subspecies tularensis is a highly virulent intracellular bacterial pathogen, causing the disease tularemia. However, a safe and effective vaccine for routine application against F. tularensis has not yet been developed. We have recently constructed the deletion mutants for the DsbA homolog protein (Delta dsbA/FSC200) and a hypothetical protein IglH (Delta iglH/FSC200) in the type B F. tularensis subsp. holarctica FSC200 strain, which exerted different protection capacity against parental virulent strain. In this study, we further investigated the immunological correlates for these different levels of protection provided by Delta dsbA/FSC200 and Delta iglH/FSC200 mutants. Our results show that Delta dsbA/FSC200 mutant, but not Delta iglH/FSC200 mutant, induces an early innate inflammatory response leading to strong Th1-like antibody response. Furthermore, vaccination with Delta dsbA/FSC200 mutant, but not with Delta iglH/FSC200, elicited protection against the subsequent challenge with type A SCHU S4 strain in mice. An immunoproteomic approach was used to map a spectrum of antigens targeted by Th1-like specific antibodies, and more than 80 bacterial antigens, including novel ones, were identified. Comparison of tularemic antigens recognized by the Delta dsbA/FSC200 post-vaccination and the SCHU S4 post-challenge sera then revealed the existence of 22 novel SCHU S4 specific antibody clones.
Trvalý link: http://hdl.handle.net/11104/0297776